News & Events

• August 17, 2015
  

  New Clinical Infectious Diseases Journal Supplement Highlights Hollow Fiber System Model for Tuberculosis

  New Clinical Infectious Diseases Journal Supplement Highlights Hollow Fiber System Model for Tuberculosis   The achievements and ongoing efforts of C-Path’s Critical Path to TB Drug Regimens (CPTR) initiative’s work on the Hollow Fiber System Model for Tuberculosis (HFS-TB) are detailed in a new supplement published in the Clinical Infectious Diseases journal. The supplement includes......
• June 1, 2015
  

  Critical Path Institute Secures Regulatory Support For Autosomal Dominant Polycystic Kidney Disease (ADPKD) Biomarker

  TUCSON, Ariz., June 1, 2015 — The Critical Path Institute (C-Path) announced today that the U.S. Food and Drug Administration (FDA) has issued a Letter of Support to C-Path’s Polycystic Kidney Disease Outcomes Consortium (PKDOC) for the use of total kidney volume (TKV) as a prognostic biomarker to select patients for clinical trials of new therapies for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
  ADPKD is a debilitating genetic disease affecting more than 600,000 Americans and 12 million people worldwide. It is characterized by progressive enlargement of the kidneys due to the formation and growth of cysts. TKV is a measurement of the impact of ADPKD on the size of the kidneys and is believed to be predictive of a future decline in kidney function

• April 20, 2015
  

  C-Path featured in the April 16 newsletter of the Multi-Regional Clinical Trials Center at Harvard

• March 1, 2015
  

  Catalyzing The Critical Path Initiative: FDA’s Progress In Drug Development Activities

• February 3, 2015
  

  “International Partnership to Create Global TB Data-Sharing Platform” on p. 4 of UNITAID’s “The Market Share.”